Using brain stimulation to help COVID-19 patients with autoimmune diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of transcranial direct current stimulation (tDCS) in patients with systemic autoimmune rheumatic diseases (SARDs) who are experiencing persistent symptoms after recovering from COVID-19. The focus is on alleviating symptoms such as fatigue and general pain, which are common in both post-acute COVID-19 syndrome and SARDs. The study aims to determine if tDCS can provide relief for these patients, as there have been no prior evaluations of this technique in this specific population. Participants will receive tDCS treatment in a controlled setting to assess its effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with well-defined ARDs (rheumatoid arthritis, sclerosis systemic, Sjögren syndrome, spondyloarthritis, systemic lupus erythematosus, systemic vasculitis, and systemic autoimmune myopathies)
* Fatigue or general pains.

Exclusion Criteria:

* Neoplasia, using heart pacemarker, using visceral metalic clips, infections (HIV, HTLV-1, hepatitis), pregnance, previous historical of convulsions or epilepsies

Where it's running

• Samuel K Shinjo
  São Paulo, Brazil Recruiting

Study contacts

• Principal investigator: Samuel K Shinjo, PhD — Sao Paulo University
• Study coordinator: Samuel K Shinjo, PhD
• Email: samuel.shinjo@usp.br
• Phone: 551130617176

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Combined e-Learning and Virtual Reality Training to Improve Rheumatology Provider Communication

  This trial tests whether a combined online course and VR training helps rheumatology providers communicate better with patients and whether patients rate their communication more highly after training.

  Recruiting Leiden University Medical Center · Leiden, South Holland · NCT07835256

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• Music-4-MS: A 12-week music-based program to support thinking skills in people with MS

  A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.

  Recruiting University of Texas at Austin · Austin, Texas · NCT07759115

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.